Positioning no disclosures inside 60 days, left as found
Options put/call open interest 3.81, read 2026-11-04
Ethical does not pass the values gate
Price48.42 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-01Read Distribution54.87-11.8% to today ✓Markdown gives way to Distribution after a 36% slide in 3 weeks
2026-10-11Read Markdown85.93-43.7% to today ✓Accumulation gives way to Markdown
2026-10-02Read Accumulation85.93-43.7% to today Markup gives way to Accumulation
2026-08-26Read Markup88.04-45.0% to today Distribution gives way to Markup after a 12% slide in 8 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
CoreWeave Inc holds its Distribution at $48.42. The statistical read favours the sellers, held for 45 days.
As held on the ledger · 2026-11-04
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 45 days
Price at the screen
$48.42
Valuation
N/A trailing · -27.30 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
60.49%
Below 33%
Interest-bearing debt is 60.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.07%
Below 33%
Cash held in interest-bearing accounts and securities is 0.1% of assets, under the one-third limit.
Pass
Receivables
12.77%
Below 49%
Money owed to the company is 12.8% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
CoreWeave's business is in a permissible area, but its interest-bearing debt is about 60% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when CRWV's ethical verdict changes
Today CRWV does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.42x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
AI cloud demand runs into heavy losses
Every time a model trainer spins up fresh GPUs the need for fast flexible capacity rises. CoreWeave built its platform to serve exactly that slice of demand and revenue is rising at 112 percent. Yet the numbers still show losses.
Forward earnings sit at minus 50 times sales while profit margins run at minus 26 percent and return on equity at minus 41 percent. Analysts cluster around a 140 dollar target but our screen finds no opportunity worth taking. The narrow moat offers little protection against larger cloud rivals.
High growth cannot mask the cash burn or the fact that current returns remain deeply negative. Any margin of safety rests on future promises rather than present results. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CRWV trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Distribution$48.42-9.9%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 9.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (33 analysts) rates it buy, with a mean price target of $140. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Distribution$53.74-2.1%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (33 analysts) rates it buy, with a mean price target of $140. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Distribution$54.87+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (33 analysts) rates it buy, with a mean price target of $140. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (33 analysts) rates it buy, with a mean price target of $140. Insiders have been net sellers over the past quarter.
2026-10-25Markdown$61.12-12.3%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (33 analysts) rates it buy, with a mean price target of $140. Insiders have been net sellers over the past quarter.
2026-10-18Markdown$69.69-18.9%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 18.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (33 analysts) rates it buy, with a mean price target of $140. Insiders have been net sellers over the past quarter.
2026-10-11Markdown · changed$85.93+0.0%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (33 analysts) rates it buy, with a mean price target of $140. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (33 analysts) rates it buy, with a mean price target of $140. Insiders have been net sellers over the past quarter.
2026-08-26Markup · changed$88.04+20.3%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 20.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (33 analysts) rates it buy, with a mean price target of $140. Insiders have been net sellers over the past quarter.
2026-07-25Distribution$73.21-27.2%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 27.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 38%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (33 analysts) rates it buy, with a mean price target of $140.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
